Ashwin U. Rao
19Patents
4h-index
85Co-inventors
59Inventor score
Filing activity: Jun 30, 2005 → Nov 13, 2017
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7709641B2 | NK1 antagonists | Chemistry; Metallurgy | 14 | Active |
| US8026364B2 | NK1 antagonists | Chemistry; Metallurgy | 9 | Active |
| US8754216B2 | NK1 antagonists | Chemistry; Metallurgy | 8 | Active |
| US8927559B2 | Quinazolinone-type compounds as CRTH2 antagonists | Chemistry; Metallurgy | 4 | Active |
| US7723342B2 | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia | Chemistry; Metallurgy | 3 | Expired |
| US7354922B2 | Bridged ring NK1 antagonists | Human Necessities | 3 | Expired |
| US9469629B2 | NK1 antagonists | Chemistry; Metallurgy | 2 | Active |
| US8889683B2 | Substituted quinoxalines as inhibitors of fatty acid binding protein | Chemistry; Metallurgy | 2 | Active |
| US7750015B2 | Nitrogen-containing heterocyclic compounds and methods of use thereof | Human Necessities | 2 | Active |
| US7737155B2 | Nitrogen-containing heterocyclic compounds and methods of use thereof | Chemistry; Metallurgy | 2 | Active |
| US9469615B2 | Quinoxalines and AZA-quinoxalines as CRTH2 receptor modulators | Chemistry; Metallurgy | 1 | Active |
| US8476274B2 | Biaryl spiroaminooxazoline analogues as Alpha2C adrenergic receptor modulators | Chemistry; Metallurgy | 0 | Active |
| US9290454B2 | Substituted isoquinolines as CRTH2 receptor modulators | Chemistry; Metallurgy | 0 | Active |
| US8569312B2 | Biaryl-spiroaminooxzaoline analogues as alpha 2C adrenergic receptor modulators | Chemistry; Metallurgy | 0 | Active |
| US8283360B2 | Bicyclic heterocyclic derivatives and methods of use thereof | Chemistry; Metallurgy | 0 | Active |
| US8324213B2 | Biaryl-spiroaminooxazoline analogues as alpha 2C adrenergic receptor modulators | Chemistry; Metallurgy | 0 | Active |
| US10875851B2 | Factor XIIa inhibitors | Chemistry; Metallurgy | 0 | Active |
| US10414775B2 | Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease | Chemistry; Metallurgy | 0 | Active |
| US9969711B2 | NK1 antagonists | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.